Original Research

Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory analysis

Lufuno G. Mavhandu-Ramarumo, Lisa A.M. Tambe, Nontokozo D. Matume, David Katerere, Pascal O. Bessong
Southern African Journal of HIV Medicine | Vol 22, No 1 | a1200 | DOI: https://doi.org/10.4102/sajhivmed.v22i1.1200 | © 2021 Lufuno G. Mavhandu-Ramarumo, Lisa A.M. Tambe, Nontokozo D. Matume, David Katerere, Pascal O. Bessong | This work is licensed under CC Attribution 4.0
Submitted: 23 November 2020 | Published: 08 April 2021

About the author(s)

Lufuno G. Mavhandu-Ramarumo, HIV/AIDS and Global Health Research Programme, Department of Microbiology, School of Mathematical and Natural Sciences, University of Venda, Thohoyandou, South Africa
Lisa A.M. Tambe, HIV/AIDS and Global Health Research Programme, Department of Microbiology, School of Mathematical and Natural Sciences, University of Venda, Thohoyandou, South Africa
Nontokozo D. Matume, HIV/AIDS and Global Health Research Programme, Department of Microbiology, School of Mathematical and Natural Sciences, University of Venda, Thohoyandou, South Africa
David Katerere, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Science, Tshwane University of Technology, Pretoria, South Africa
Pascal O. Bessong, HIV/AIDS and Global Health Research Programme, Department of Microbiology, School of Mathematical and Natural Sciences, University of Venda, Thohoyandou, South Africa; Center for Global Health Equity, University of Virginia, Charlottesville, United States

Abstract

Background: The proportion of individuals with a history of exposure (‘pre-exposure’) to antiretrovirals (ARVs) prior to formal initiation into antiretroviral treatment (ART) is unknown.

Objectives: This study describes the detection of ARVs in plasma and/or hair, of persons who self-reported no pre-exposure to ART at their first-time initiation onto ART in three clinics in the province of Limpopo, South Africa (SA).

Method: Concentrations of tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV) in the plasma and hair of individuals initiating ART were analysed using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Next generation sequences of HIV polymerase gene were analysed with Geneious software 11.15, and drug resistance (DR) mutations were determined according to the Stanford HIV Drug-Resistance database. Participants’ demographic data were collected on a structured questionnaire. Data that describe prior exposure to ARV were also collected by this self-reporting method.

Results: Paired blood and hair samples were collected from 77 individuals newly initiated onto ART from 2017 to 2019. We detected at least one of the drugs in the plasma or hair of 41/77 (53.2%) patients who responded with a ‘no’ to the question ‘have you received ARVs before initiation onto ART?’ Thirty-one participants (n = 31/77, 40.3%) had TDF in either plasma or hair. Emtricitabine and EFV were found in the plasma or hair of 12/77 (15.6%) and 25/77 (32.4%) of participants respectively. Six (n = 6/77, 7.792%) had all three ARVs in plasma or hair. Prevalence of DR mutations at the > 5% significance threshold level in those known to have had ARV-exposure determined by LC-MS/MS prior to ART-initiation was not significant (χ2 = 0.798; p = 0.372), when compared to those who had no prior exposure but still showed DR.

Conclusion: Antiretroviral levels in the hair of individuals initiating treatment imply prolonged prior-exposure to that ARV. The presence of ARV in plasma and hair of persons living with HIV (PLWH) who deny ARV-use, requires an explanation. A larger study at multiple sites and regular DR surveillance of ART-naïve PLWH will be necessary to confirm the generalisability of these findings to the wider South African population.


Keywords

ART; pre-exposure; HIV drug resistance; adherence; exploratory analysis

Metrics

Total abstract views: 3985
Total article views: 4463

 

Crossref Citations

1. Can routine antenatal data be used to assess HIV antiretroviral therapy coverage among pregnant women? Evaluating the validity of different data sources in the Western Cape, South Africa
Nisha Jacob, Brian Rice, Alexa Heekes, Leigh F. Johnson, Samantha Brinkmann, Tendesayi Kufa, Andrew Boulle, Muhammad Osman
PLOS ONE  vol: 19  issue: 4  first page: e0291844  year: 2024  
doi: 10.1371/journal.pone.0291844

2. Dolutegravir Resistance in African Programmatic Settings Among Patients With Failure of Dolutegravir-based ART
Richard A Murphy, Pradeep H Bedesi, Nirmala Perumal, Bernadett I Gosnell, Timothy J Hatlen, Jaysingh Brijkumar
Open Forum Infectious Diseases  vol: 11  issue: 7  year: 2024  
doi: 10.1093/ofid/ofae321

3. Preferences for services in a patient’s first six months on antiretroviral therapy for HIV in South Africa and Zambia (PREFER): research protocol for a prospective observational cohort study
Mhairi Maskew, Vinolia Ntjikelane, Allison Juntunen, Nancy Scott, Mariet Benade, Linda Sande, Pamfred Hasweeka, Prudence Haimbe, Priscilla Lumano-Mulenga, Hilda Shakewelele, Mpande Mukumbwa-Mwenechanya, Sydney Rosen
Gates Open Research  vol: 7  first page: 119  year: 2024  
doi: 10.12688/gatesopenres.14682.2

4. Moving towards the global HIV 95% viral suppression target
Pascal O Bessong, Lufuno G Mavhandu-Ramarumo
The Lancet HIV  vol: 8  issue: 12  first page: e731  year: 2021  
doi: 10.1016/S2352-3018(21)00273-3

5. The unintended outcome: a retrospective cross‐sectional study using a urine lateral flow assay to detect ART use reveals non‐disclosure of taking ART in South Africa's public health system
Nsika Sithole, Indira Govender, Matthew Spinelli, Theresa Smit, Siyabonga Cibane, Mlungisi Zwane, Njabulo Phakathi, Meighan Krows, Busisiwe Nkosi, Janet Seeley, Ruanne V. Barnabas, Mark J. Siedner, Mosa Moshabela, Connie Celum, Alison Grant, Monica Gandhi, Adrienne E. Shapiro
Journal of the International AIDS Society  vol: 28  issue: 6  year: 2025  
doi: 10.1002/jia2.26515

6. Prior antiretroviral therapy exposure among clients presenting for HIV treatment initiation in South Africa: an exploratory mixed-methods study using multiple indicators of exposure
Mariet Benade, Mhairi Maskew, Vinolia Ntjikelane, Nancy Scott, Nkosinathi Ngcobo, Brooke Nichols, Lufuno Malala, Musa Manganye, Sydney Rosen
BMC Infectious Diseases  vol: 25  issue: 1  year: 2025  
doi: 10.1186/s12879-025-11340-4

7. Preferences for services in a patient’s first six months on antiretroviral therapy for HIV in South Africa and Zambia (PREFER): research protocol for a prospective observational cohort study
Mhairi Maskew, Vinolia Ntjikelane, Allison Juntunen, Nancy Scott, Mariet Benade, Linda Sande, Pamfred Hasweeka, Prudence Haimbe, Priscilla Lumano-Mulenga, Hilda Shakewelele, Mpande Mukumbwa-Mwenechanya, Sydney Rosen
Gates Open Research  vol: 7  first page: 119  year: 2023  
doi: 10.12688/gatesopenres.14682.1

8. High prevalence of undisclosed antiretroviral drug use among individuals initiating HIV treatment in Gaborone, Botswana
Natasha O. Moraka, Sikhulile Moyo, Terence Mohammed, Kesaobaka Molebatsi, Lubbe Wiesner, Patrick T. Mokgethi, Irene Gobe, Margaret Mokomane, Salang T. Moutswi, Laone Rabatoko, Queen Leteemane, Vanessa Strachan-Amaro, Phenyo Sabone, Simani Gaseitsiwe
Frontiers in Public Health  vol: 13  year: 2025  
doi: 10.3389/fpubh.2025.1582940

9. Prior exposure to antiretroviral therapy among adult patients presenting for HIV treatment initiation or reinitiation in sub-Saharan Africa: a systematic review
Mariet Benade, Mhairi Maskew, Allison Juntunen, David B Flynn, Sydney Rosen
BMJ Open  vol: 13  issue: 11  first page: e071283  year: 2023  
doi: 10.1136/bmjopen-2022-071283

10. Dolutegravir regimens have transformed treatment, but ongoing drug resistance research is required to maintain success
Gert U. Van Zyl, Lauren Jennings, Helena Rabie, Catherine Orrell
AIDS  vol: 39  issue: 4  first page: 337  year: 2025  
doi: 10.1097/QAD.0000000000004099